Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?

Detalles Bibliográficos
Autor principal: Brass, Eric P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687289/
https://www.ncbi.nlm.nih.gov/pubmed/23695815
http://dx.doi.org/10.2337/dc13-0891
_version_ 1782273898431119360
author Brass, Eric P.
author_facet Brass, Eric P.
author_sort Brass, Eric P.
collection PubMed
description
format Online
Article
Text
id pubmed-3687289
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-36872892014-07-01 Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync? Brass, Eric P. Diabetes Care Commentary American Diabetes Association 2013-07 2013-06-12 /pmc/articles/PMC3687289/ /pubmed/23695815 http://dx.doi.org/10.2337/dc13-0891 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Commentary
Brass, Eric P.
Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
title Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
title_full Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
title_fullStr Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
title_full_unstemmed Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
title_short Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?
title_sort assessing the benefit-risk for new drugs: are the fda's endocrinologic and metabolic drugs advisory committee and the division of metabolism and endocrinology products in sync?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687289/
https://www.ncbi.nlm.nih.gov/pubmed/23695815
http://dx.doi.org/10.2337/dc13-0891
work_keys_str_mv AT brassericp assessingthebenefitriskfornewdrugsarethefdasendocrinologicandmetabolicdrugsadvisorycommitteeandthedivisionofmetabolismandendocrinologyproductsinsync

Ejemplares similares